Rho-kinase inhibitors show promise in pulmonary hypertension

ISSN： 1354-3784

Source： Expert Opinion on Investigational Drugs, Vol.14, Iss.9, 2005-09, pp. : 1157-1159

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

The Role of the RhoA/rho-kinase Pathway in Pulmonary Hypertension

Current Drug Discovery Technologies, Vol. 6, Iss. 1, 2009-03 ,pp. : 59-71

Bentham Science Publishers

Access to resources Recommend Favorite

Therapeutic Potential of Rho-Kinase Inhibitors in Cardiovascular Diseases

By Hirooka Yoshitaka Shimokawa Hiroaki

American Journal of Cardiovascular Drugs, Vol. 5, Iss. 1, 2005-01 ,pp. : 31-39

Adis International

Access to resources Recommend Favorite

Rho-kinase inhibitors offer a new approach in the treatment of glaucoma

By Challa Pratap Arnold John J

Expert Opinion on Investigational Drugs, Vol. 23, Iss. 1, 2014-01 ,pp. : 81-95

Informa Healthcare

Access to resources Recommend Favorite

Effects of the Rho-kinase inhibitors, Y-27632 and fasudil, on the corpus cavernosum from diabetic mice

By Buyukafsar K. Un I.

European Journal of Pharmacology, Vol. 472, Iss. 3, 2003-07 ,pp. : 235-238

Elsevier

Access to resources Recommend Favorite

Targeting RhoA/ROCK pathway in pulmonary arterial hypertension

By Antoniu Sabina Antonela

Expert Opinion on Therapeutic Targets, Vol. 16, Iss. 4, 2012-04 ,pp. : 355-363

Informa Healthcare

Access to resources Recommend Favorite